biostudies-literatureUnknown86(1)Seitz K<h4>Background</h4>For the first time, an S3 guideline on complementary medicine in oncology was published in 2021, 2024 in May version 2.0 was published. The broad spectrum of complementary and integrative medicine was presented at the highest level of evidence, the respective established interventions were comprehensively addressed, and recommendations were made in the case of sufficient data availability. The guideline also contains a questionnaire for a risk-adapted evaluation of utilized CIM (complementary and integrative medicine) interventions. In this article, the clinical validation of this questionnaire from the guideline is carried out, as well as a descriptive analysis of utilization of CIM interventions in a cohort with gynecologial cancer.<h4>Methods</h4>The present study is Geburtshilfe und Frauenheilkunde35-44https://www.ebi.ac.uk/biostudies/studies/S-EPMC12803761biostudies-literatureValidation of the Questionnaire for the Structured Assessment of the Use of Complementary Medicine Methods and Procedures in Patients from the S3 Guideline Complementary Medicine in Oncology and Practical Use of it in Patients with Gynecological Cancer.PMC12803761Au KSeitz KBeierlein MHack CCBruckner LTheuser AKEmons JBeckmann MWFasching PAfalseValidation of the Questionnaire for the Structured Assessment of the Use of Complementary Medicine Methods and Procedures in Patients from the S3 Guideline Complementary Medicine in Oncology and Practical Use of it in Patients with Gynecological Cancer.<h4>Background</h4>For the first time, an S3 guideline on complementary medicine in oncology was published in 2021, 2024 in May version 2.0 was published. The broad spectrum of complementary and integrative medicine was presented at the highest level of evidence, the respective established interventions were comprehensively addressed, and recommendations were made in the case of sufficient data availability. The guideline also contains a questionnaire for a risk-adapted evaluation of utilized CIM (complementary and integrative medicine) interventions. In this article, the clinical validation of this questionnaire from the guideline is carried out, as well as a descriptive analysis of utilization of CIM interventions in a cohort with gynecologial cancer.<h4>Methods</h4>The present study is 2026-01-01T00:00:00Z2026 Jan2026-06-10T05:30:09.736Z2026-06-10T03:07:28.177ZS-EPMC128037614154210510.1055/a-2717-7656